Yamada, Ikuhiro
Morizane, Chigusa
Okusaka, Takuji
Mizusawa, Junki
Kataoka, Tomoko
Ueno, Makoto
Ikeda, Masafumi
Okano, Naohiro
Todaka, Akiko
Shimizu, Satoshi
Mizuno, Nobumasa
Sekimoto, Mitsugu
Tobimatsu, Kazutoshi
Yamaguchi, Hironori
Nishina, Tomohiro
Shirakawa, Hirofumi
Kojima, Yasushi
Oono, Takamasa
Kawamoto, Yasuyuki
Furukawa, Masayuki
Iwai, Tomohisa
Sudo, Kentaro
Okamura, Keiya
Yamashita, Tatsuya
Kato, Naoya
Shioji, Kazuhiko
Shimizu, Kyouko
Nakagohri, Toshio
Kamata, Ken
Ishii, Hiroshi
Furuse, Junji
Yamada, Ikuhiro
Morizane, Chigusa
Okusaka, Takuji
Mizusawa, Junki
Kataoka, Tomoko
Ueno, Makoto
Ikeda, Masafumi
Ozaka, Masato
Okano, Naohiro
Sugimori, Kazuya
Todaka, Akiko
Shimizu, Satoshi
Mizuno, Nobumasa
Sekimoto, Mitsugu
Sano, Keiji
Tobimatsu, Kazutoshi
Katanuma, Akio
Sakai, Kenji
Yamaguchi, Hironori
Nishina, Tomohiro
Shirakawa, Hirofumi
Kojima, Yasushi
Oono, Takamasa
Kawamoto, Yasuyuki
Furukawa, Masayuki
Iwai, Tomohisa
Sudo, Kentaro
Okamura, Keiya
Yamashita, Tatsuya
Yasuda, Ichirou
Takahashi, Hidenori
Kato, Naoya
Shioji, Kazuhiko
Shimizu, Kyouko
Nakagohri, Toshio
Kamata, Ken
Ishii, Hiroshi
Furuse, Junji
,
Article History
Received: 17 August 2021
Accepted: 23 December 2021
First Online: 19 January 2022
Competing interests
: CM reports grants and personal fees from Yakult, MSD, J-Pharma, AstraZeneca and Taiho, grants from ONO, Eisai, Merck biopharma and Daiichi Sankyo, personal fees from Teijin, Novartis and Abbvie, outside the submitted work. TO reports grants and personal fees from Taiho and Bristol-Myers Squibb, personal fees from Yakult, Pfizer, Takeda and Eli Lilly, during the conduct of the study; grants and personal fees from AstraZeneca, Eisai, MSD and Dainippon Sumitomo, grants from Baxter, personal fees from Nippon Servier, Meiji Seika, Shire, AbbVie, Incyte, ONO, Daiichi Sankyo, Takara Bio, Chugai, Teijin, Nippon Shinyaku, Novartis, Bayer and Mundipharma, outside the submitted work. JM reports grants from Ministry of Health, Labour and Welfare (MHLW), Japan and Japan AMED, during the conduct of the study; personal fees from Chugai and Taiho, outside the submitted work. MU reports grants and personal fees from Taiho, AstraZeneca, Merck Serono, MSD, Daiichi Sankyo, Ono and Chugai, grants from Astellas, Eisai, Dainippon Sumitomo and Incyte, personal fees from Nihon Servier, outside the submitted work. MI reports personal fees and other from Eisai, MSD, Eli Lilly, Yakult and ASLAN, personal fees from GSK, other from Merck Serono, Ono, J-Pharma and AstraZeneca, during the conduct of the study; personal fees and other from EA Pharma, Yakult, Nihon Servier, Chugai, Bristol-Myers Squibb, Novartis, Bayer and Takeda, personal fees from Teijin, Astellas, Sumitomo Dainippon, Otsuka and Taiho, other from Pfizer, Merus N.V., Ono, Delta-Fly Pharma and Chiome Bioscience, outside the submitted work. NO reports personal fees from Taiho, Eli Lilly, Kyowa Hakko Kirin, Eisai, Bayer, Chugai, J-Pharma, Takeda and GSK, outside the submitted work. SS reports grants from Yakult, Incyte, AstraZeneca and Delta-Fly Pharma, outside the submitted work. NM reports grants from MHLW, Japan and Taiho, during the conduct of the study; grants and personal fees from Novartis, MSD and Yakult, grants from NanoCarrier, Dainippon Sumitomo, ASLAN, Incyte and Ono, personal fees from AstraZeneca and Teijin, outside the submitted work. TN reports grants and personal fees from Taiho, Chugai, Ono, Bristol Myers Squibb, Eli Lilly, grants from MSD, Dainippon sumitomo and AstraZeneca, outside the submitted work. YK reports grants from Beigene, Incyte, Ono, Takeda, Daiichi Sankyo and Eisai, personal fees from Chugai, Sanofi, Bristol-Myers Squibb, Taiho, Eli Lilly and Yakult, personal fees and non-financial support from AstraZeneca, outside the submitted work. YK reports personal fees from Takeda, Merck Biopharma, Eli Lilly, Taiho and Yakult, outside the submitted work. TY reports personal fees from Eli Lilly, outside the submitted work. HI reports personal fees from Taiho, Eli Lilly, Yakult, Daiichi Sankyo, Kyowa Hakko Kirin, Mochida and Hospira Japan, during the conduct of the study; personal fees from Yakult and Taiho, outside the submitted work. JF reports grants from the National Cancer Center and the MHLW, Japan, during the conduct of the study; grants from Ono, MSD, Merck Bio, J-Pharma, Taiho, Takeda, Chugai, Astra Zeneca, Yakult, Eisai, Daiichi Sankyo, Mochida, Sanofi, Sumitomo Dainippon, Bayer, Astellas and Incyte, personal fees from Ono, Bayer, Eisai, Eli Lilly, MSD, Yakult, Chugai, Novartis, Astra Zeneca, Pfizer, Takeda, Taiho, Sanofi, Mylan EPD, EA Pharma, Kyowa Hakko Kirin, Daiichi Sankyo, Teijin, Servier Japan and Incyte, outside the submitted work. All other authors declare no competing interests.